Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Axsome Therapeutics: Clinical Trials & FDA Approval Profile

Axsome Therapeutics (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (10 recruiting now), 16 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.9%
Median Closed Enrollment vs National (145 pts)242 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Axsome Therapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)10 (10)
Completed vs Stopped Early16 / 2 (6.9%)
Median Closed Actual Enrollment242 participants
Physical Hospital Site Disclosure1.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Axsome Therapeutics Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI